Open Access Open Access  Restricted Access Subscription Access

An Essential Parameters of Anti-Epileptic Drug Monitoring Include Objectives, Functions, Issues of Concerns, Drug-Drug Interactions, Anti-Seizure Medication Compliance, Clinical Significance and Health Care Team Outcomes

Moni Theresa Tsappidi, Muralinath E., Srinivas G., Guruprasad M., Ramanjaneyulu D. V.

Abstract


Ever since antiseizure drugs were developed, antiepileptic drug-level monitoring has been essential to seizure treatment. Although several factors influence serum concentrations, maintaining medication levels, particularly within therapeutic margins, is a difficulty. Together with absorption, distribution, metabolism, and excretion, pharmacokinetic parameters have a major impact on drug levels. Dieting, additional medications, and nutritional status all have a significant impact on how these processes change. Particularly when several medications are taken at once, drug metabolism with the aid of systems like cytochrome P450 and conjugation processes is crucial. The foundation for assessing epilepsy is clinical examination, which is bolstered by magnetic resonance imaging and electroencephalograms. Drug levels act as an adjunct to determine efficacy in particular circumstances. Guidelines on best practices for therapeutic drug monitoring are organized by the International League Against Epilepsy (ILAE), which also highlights situations in which this method is particularly beneficial. This exercise highlights the significance of comprehending these recommendations as well as current research on interpreting drug levels while taking the patient's characteristics and treatment objectives into account. It's crucial to communicate treatment goals and the rationale behind medication monitoring effectively. The usefulness, variety, and applicability of antiepileptic medication level monitoring are examined in this activity, particularly in a range of clinical settings.


Full Text:

PDF

References


French, J. A., & Perucca, E. (2020). Time to start calling things by their own names? The case for antiseizure medicines. Epilepsy Currents, 20(2), 69–72. https://doi.org/10.1177/1535759720905516 aepi.biomedcentral.com+2pubmed.ncbi.nlm.nih.gov+2journals.sagepub.com+2

Benbadis, S. R., Beniczky, S., Bertram, E., MacIver, S., & Moshé, S. L. (2020). The role of EEG in patients with suspected epilepsy. Epileptic Disorders, 22(2), 143–155. https://doi.org/10.1684/epd.2020.1151 sciencedirect.com+7jle.com+7colab.ws+7

Patsalos, P. N., Berry, D. J., Bourgeois, B. F., Cloyd, J. C., Glauser, T. A., Johannessen, S. I., Leppik, I. E., Tomson, T., & Perucca, E. (2008). Antiepileptic drugs—Best practice guidelines for therapeutic drug monitoring: A position paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia, 49(7), 1239–1276.

Beydoun, A., Uthman, B. M., & Sackellares, J. C. (1995). Gabapentin: Pharmacokinetics, efficacy, and safety. Clinical Neuropharmacology, 18(6), 469–481.

Milosheska, D., & Roškar, R. (2023). Simple HPLC UV method for therapeutic drug monitoring of 12 antiepileptic drugs and their main metabolites in human plasma. Molecules, 28(23). https://doi.org/10.3390/molecules28237123

St. Louis, E. K. (2009). Monitoring antiepileptic drugs: A level-headed approach. Current Neuropharmacology, 7(2), 115–119.

Patel, A. R., & Nagalli, S. (2024, May 6). Valproate toxicity. In StatPearls. StatPearls Publishing.

Stepanova, D., & Beran, R. G. (2015). The benefits of antiepileptic drug (AED) blood level monitoring to complement clinical management of people with epilepsy. Epilepsy & Behavior, 42, 7–9.

Atif, M., Azeem, M., & Sarwar, M. R. (2016). Potential problems and recommendations regarding substitution of generic antiepileptic drugs: A systematic review of the literature. SpringerPlus, 5, 182. https://doi.org/10.1186/s40064-016-1905-5

Walters, R. J., Hutchings, A. D., Smith, D. F., & Smith, P. E. (2004). Inappropriate requests for serum anti epileptic drug levels in hospital practice. QJM, 97(6), 337–341. https://doi.org/10.1093/qjmed/hch061

Krasowski, M. D. (2010). Therapeutic drug monitoring of the newer anti epilepsy medications. Pharmaceuticals (Basel), 3(6), 1909–1935. https://doi.org/10.3390/ph3061909

Schmidt, D., & Haenel, F. (1984). Therapeutic plasma levels of phenytoin, phenobarbital, and carbamazepine: Individual variation in relation to seizure frequency and type. Neurology, 34(9), 1252–1255.

Woo, E., Chan, Y. M., Yu, Y. L., Chan, Y. W., & Huang, C. Y. (1988). If a well stabilized epileptic patient has a subtherapeutic antiepileptic drug level, should the dose be increased? A randomized prospective study. Epilepsia, 29(2), 129–139.

Fratoni, A. J., Colmerauer, J. L., Linder, K. E., Nicolau, D. P., & Kuti, J. L. (2023). A retrospective case series of concomitant carbapenem and valproic acid use: Are best practice advisories working? Journal of Pharmacy Practice, 36(3), 537–541. https://doi.org/10.1177/08971900231165176

Armstrong, A. G., Kalia, R., & Troutman, M. (2022). Lamotrigine drug interactions: Ignorance is not bliss. Kansas Journal of Medicine, 15(1), 109–111. https://doi.org/10.17161/kjm.v15i1.15965

Mostacci, B., Esposto, R., Lello, S., Bisulli, F., Licchetta, L., & Tinuper, P. (2018). Estrogen related seizure exacerbation following hormone therapy for assisted reproduction in women with epilepsy. Seizure, 61, 200–202. https://doi.org/10.1016/j.seizure.2018.08.010

King, A., Bachman, E., Macken, M. P., Lee, J., & Gerard, E. E. (2020). Contraceptive vaginal ring reduces lamotrigine levels. Epilepsy & Behavior, 111, 107162. https://doi.org/10.1016/j.yebeh.2020.107162

Gunasekera, C. L., Sirven, J. I., & Feyissa, A. M. (2023). The evolution of antiseizure medication therapy selection in adults: Is artificial intelligence assisted antiseizure medication selection ready for prime time? Journal of Central Nervous System Disease, 15, 11795735231209209. https://doi.org/10.1177/11795735231209209

Jannuzzi, G., Cian, P., Fattore, C., Gatti, G., Bartoli, A., Monaco, F., & Perucca, E. (2000). A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy: The Italian TDM Study Group in Epilepsy. Epilepsia, 41(2), 222–230.

Sherwin, A. L., Robb, J. P., & Lechter, M. (1973). Improved control of epilepsy by monitoring plasma ethosuximide. Archives of Neurology, 28(3), 178–181. https://doi.org/10.1001/archneur.1973.00490030090009

Eatock, J., & Baker, G. A. (2007). Managing patient adherence and quality of life in epilepsy. Neuropsychiatric Disease and Treatment, 3(1), 117–131. https://doi.org/10.2147/NDT.S2715

Fraser, S. (2010). Concordance, compliance, preference or adherence. Patient Preference and Adherence, 4, 95–96. https://doi.org/10.2147/PPA.S10323

Aronson, J. K. (2007). Compliance, concordance, adherence. British Journal of Clinical Pharmacology, 63(4), 383–384. https://doi.org/10.1111/j.1365-2125.2007.02832.x

Fisher, R. S. (2010). Tracking epilepsy with an electronic diary. Acta Paediatrica, 99(4), 516–518. https://doi.org/10.1111/j.1651-2227.2009.01640.x

Al Aqeel, S., Gershuni, O., Al Sabhan, J., & Hiligsmann, M. (2020). Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy. Cochrane Database of Systematic Reviews, (10), CD008312. https://doi.org/10.1002/14651858.CD008312.pub3


Refbacks

  • There are currently no refbacks.